After the diagnosis: Adherence and persistence with hypertension therapy

American Journal of Managed Care

Volumn 11, Issue SUPPL. 13, 2005, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LERCANIDIPINE; LISINOPRIL; PROTON PUMP INHIBITOR; STATINE DERIVATIVE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COUGHING; DIZZINESS; DRUG CLASSIFICATION; DRUG COST; DRUG TOLERABILITY; HEADACHE; HEALTH INSURANCE; HUMAN; HYPERTENSION; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ANTIHYPERTENSIVE AGENTS; COUGH; DIZZINESS; DRUG ADMINISTRATION SCHEDULE; FEES, PHARMACEUTICAL; FEMALE; HEADACHE; HUMANS; HYPERTENSION; INSURANCE, PHARMACEUTICAL SERVICES; MALE; PATIENT COMPLIANCE; UNITED STATES;

EID: 28344438169     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656.
2. Thompson DW, Furlan AJ. Clinical epidemiology of stroke. Neurol Clin. 1996;14:309-315.
3. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens. 1999;12:665-672.
4. Marmot MG, Poulter NR. Primary prevention of stroke. Lancet. 1992;339:344-347.
5. Thaker D, Frech F, Suh D, et al. Prevalence of Hypertension and Ethnic Differences in Sociodemographic and Cardiovascular Health Characteristics of US Hypertensives. Am J Hypertens. 2005;18(suppl 1):A117.
6. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health; 1997.
7. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31-37.
8. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16:439-444.
9. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther. 2002;24:1347-1357; discussion 1346.
10. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
11. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, Tex; 2005.
12. World Health Organization. Adherence to Medication: Evidence for Action. Geneva; 2003.
13. Gregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001;23:71 5-726.
14. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357-362.
15. Lip GY, Beevers DG. Doctors, nurses, pharmacists and patients-the Rational Evaluation and Choice in Hypertension (REACH) survey of hypertension care delivery. Blood Press Suppl. 1997;1:6-10.
16. Wallenius SH, Vainio KK, Korhonen MJ, Hartzema AG, Enlund HK. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother. 1995;29:1213-121 7.
17. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984; 6:592-599.
18. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care. 1998;4:1563-1568.
19. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:1999-2010.
20. Esposti LD, Di Martino M, Saragoni S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various anti-hypertensive therapies. J Clin Hypertens (Greenwich). 2004;6:76-84.
21. Thaker D, Frech F, Gause D, Zhang W. Patient adherence and persistence with antihypertensive agents: a comparison of agents in different therapeutic classes. Am J Hypertens. 2005;18(5 suppl 1):A117.
22. Borghi C, Prandin MG, Costa FV, et al. Compliance of antihypertensive treatment and monotherapy. Behaviour of the calcium-channel blocker lercanidipine. Am J Hypertens. 2005;18(5 suppl 1):A51.
23. Krousel-Wood M, Hyre A, Muntner P, Morisky D. Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr Opin Cardiol. 2005;20:296-300.
24. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36:1138-1161.
25. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722-732.
26. Morrison A, Wertheimer A, Berger M. Interventions to improve antihypertensive drug adherence: a quantitative review of trials. Formulary 2000. 2000;35:234-255.
27. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
28. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.